- Home
- CALC vs MDCX Comparison
CALC vs MDCX Comparison
Compare CALC & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CALC | MDCX |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | United States |
| Employees | N/A | 12 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.3M | 26.2M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | CALC | MDCX |
|---|---|---|
| Price | $0.61 | $0.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $10.00 | ★ $23.50 |
| AVG Volume (30 Days) | 459.7K | ★ 8.6M |
| Earning Date | 03-03-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $0.37 |
| 52 Week High | $7.20 | $8.90 |
Technical Indicators
Market Signals| Indicator | CALC | MDCX |
|---|---|---|
| Relative Strength Index (RSI) | 32.41 | 31.61 |
| Support Level | $0.49 | $0.37 |
| Resistance Level | $0.79 | $1.43 |
| Average True Range (ATR) | 0.09 | 0.11 |
| MACD | 0.08 | -0.00 |
| Stochastic Oscillator | 9.67 | 15.38 |
Price Performance
Historical ComparisonAbout CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
About MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.